|D000787||Angina Pectoris NIH||0.71|
|D003324||Coronary Artery Disease NIH||0.33|
There is one clinical trial.
The purpose of this study is to determine whether a single intracoronary infusion of an adenovirus serotype 5 virus expressing the gene for human fibroblast growth factor-4 (Ad5FGF-4) is effective in improving angina-limited exercise duration, angina functional class, frequency of angina attacks, frequency of nitroglycerin usage, and quality of life. Half of the study participants will receive Ad5FGF-4, and half will receive placebo. The primary endpoint is the change from baseline to Month 6 in Exercise Tolerance Test (ETT) duration. Long-term safety of Ad5FGF-4 will also be assessed.
Description: Modified Bruce Protocol with exercise duration limited by angina or angina equivalentMeasure: Change in Exercise Tolerance Test (ETT) duration Time: Baseline and Month 6
Description: Canadian Cardiovascular Society (CCS) angina classificationMeasure: Change in patient functional status (CCS class) Time: Baseline and Month 6
Description: Average weekly angina episodesMeasure: Change in weekly angina frequency Time: Baseline and Month 6
Description: Average weekly nitroglycerin usageMeasure: Change in weekly nitroglycerin usage Time: Baseline and Month 6
Description: Seattle Angina QuestionnaireMeasure: Change in quality of life Time: Baseline and Month 6
Description: Adverse events and clinical laboratory testingMeasure: Safety of Ad5FGF-4 Time: Through Month 6
Description: Occurrence of clinically significant eventsMeasure: Long-term safety of Ad5FGF-4 Time: Through Month 60
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports